3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Head and Neck Neoplasms
1
Head and Neck Carcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
12
Docetaxel
7
durvalumab
5
Gemcitabine
5
Trastuzumab
4
Radiotherapy
4
Surveys and Questionnaires
3
Magnetic Resonance Spectroscopy
3
tremelimumab
2
tisotumab vedotin
2
pertuzumab
2
motexafin gadolinium
2
cemiplimab
2
X-Rays
2
TH 302
2
Ritonavir
2
Pemetrexed
2
Nivolumab
2
Ipilimumab
2
Interviews as Topic
2
Injections
2
Immunoglobulin G
2
Cryosurgery
2
Cisplatin
2
Bortezomib
2
Biopsy
2
Bariatric Surgery
2
zenocutuzumab
1
yeast-CEA vaccine
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Solutions
×
Head & Neck
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled